Hydrogel dual delivered celecoxib and anti-PD-1 synergistically improve antitumor immunity

Acquired Resistance to Fractionated Radiotherapy Can Be Overcome by Concurrent PD-L1 Blockade

(2014) S. J. Dovedi et al.   CANCER RESEARCH

Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in mice

(2014) Liufu Deng et al.   JOURNAL OF CLINICAL INVESTIGATION

Intravenous immunoglobulin expands regulatory T cells via induction of cyclooxygenase-2-dependent prostaglandin E2 in human dendritic cells

(2013) J. Trinath et al.   BLOOD

Chronic inflammation and cancer: suppressing the suppressors

(2013) Michal Baniyash et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Interleukin-1  Promotes Skeletal Colonization and Progression of Metastatic Prostate Cancer Cells with Neuroendocrine Features

(2013) Q. Liu et al.   CANCER RESEARCH

Therapeutic PD-1 Pathway Blockade Augments with Other Modalities of Immunotherapy T-Cell Function to Prevent Immune Decline in Ovarian Cancer

(2013) J. Duraiswamy et al.   CANCER RESEARCH

Intratumoral Anti-CTLA-4 Therapy: Enhancing Efficacy While Avoiding Toxicity

(2013) A. Marabelle et al.   CLINICAL CANCER RESEARCH

T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment

(2013) Joel Crespo et al.   CURRENT OPINION IN IMMUNOLOGY

Algisyl-LVR™ with coronary artery bypass grafting reduces left ventricular wall stress and improves function in the failing human heart

(2013) Lik Chuan Lee et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells

(2013) Erin E. West et al.   JOURNAL OF CLINICAL INVESTIGATION

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

(2013) Omid Hamid et al.   NEW ENGLAND JOURNAL OF MEDICINE

Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells

(2013) S. Spranger et al.   Science Translational Medicine

Chemokine Cxcl9 attenuates liver fibrosis-associated angiogenesis in mice

(2012) Hacer Sahin et al.   HEPATOLOGY

Local targets for immune therapy to cancer: Tumor draining lymph nodes and tumor microenvironment

(2012) Marieke F. Fransen et al.   INTERNATIONAL JOURNAL OF CANCER

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape

(2012) J. M. Taube et al.   Science Translational Medicine

New insights into chronic inflammation-induced immunosuppression

(2012) Julia Kanterman et al.   SEMINARS IN CANCER BIOLOGY

Blockade of programmed death receptor-1 signaling restores expression of mostly proinflammatory cytokines in anergic cytomegalovirus-specific T cells

(2012) J. Dirks et al.   Transplant Infectious Disease

Know thy enemy

(2012) Andrea Facciabene et al.   OncoImmunology

PGE2-Induced CXCL12 Production and CXCR4 Expression Controls the Accumulation of Human MDSCs in Ovarian Cancer Environment

(2011) N. Obermajer et al.   CANCER RESEARCH

Local Activation of CD8 T Cells and Systemic Tumor Eradication without Toxicity via Slow Release and Local Delivery of Agonistic CD40 Antibody

(2011) M. F. Fransen et al.   CLINICAL CANCER RESEARCH

Expression of aldehyde dehydrogenase and CD133 defines ovarian cancer stem cells

(2011) Ilona Kryczek et al.   INTERNATIONAL JOURNAL OF CANCER

Selective inhibition of cyclooxygenase-2 suppresses metastatic disease without affecting primary tumor growth in a murine model of Ewing sarcoma

(2011) Amir S. Gendy et al.   JOURNAL OF PEDIATRIC SURGERY

Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy

(2011) J. Stagg et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Alginate: Properties and biomedical applications

(2011) Kuen Yong Lee et al.   PROGRESS IN POLYMER SCIENCE

Selective COX-1 Inhibition: A Therapeutic Target to be Reconsidered

(2010) M. G. Perrone et al.   CURRENT MEDICINAL CHEMISTRY

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

(2010) Julie R. Brahmer et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma

(2010) Richard E. Royal et al.   JOURNAL OF IMMUNOTHERAPY

Measurement of cyclooxygenase inhibition using liquid chromatography–tandem mass spectrometry

(2010) Hongmei Cao et al.   JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors

(2010) M. A. Curran et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Recent advances and hurdles in melanoma immunotherapy

(2009) Camilla Jandus et al.   Pigment Cell & Melanoma Research

Autologous chondrocyte implantation in a novel alginate-agarose hydrogel

(2008) T. A. S. Selmi et al.   JOURNAL OF BONE AND JOINT SURGERY-BRITISH VOLUME

Treatment of Advanced Hormone-Sensitive Breast Cancer in Postmenopausal Women With Exemestane Alone or in Combination With Celecoxib

(2008) Luc Yves Dirix et al.   JOURNAL OF CLINICAL ONCOLOGY